文献速递炎症性肠病

维持治疗期间英夫利西单抗谷浓度与溃疡性结肠炎内镜及组织学愈合相关

Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2017-12-06

本多中心回顾性队列研究纳入2008年2月至2016年3月接受英夫利西单抗维持治疗的中重度溃疡性结肠炎患者,评估维持期谷浓度与内镜及组织学愈合的关联。结果显示愈合组谷浓度显著更高,谷浓度≥7.5 μg/mL和≥10.5 μg/mL分别为内镜愈合和组织学愈合的独立相关因素。

要点

  • 内镜愈合者英夫利西单抗谷浓度中位数11.3 μg/mL,未愈合者6.3 μg/mL,差异显著。
  • 组织学愈合者谷浓度中位数11.1 μg/mL,未愈合者6.7 μg/mL,差异显著。
  • 谷浓度≥7.5 μg/mL与内镜愈合独立相关(OR 4.3),≥10.5 μg/mL与组织学愈合独立相关(OR 3.8)。

核心结论

  • 维持治疗期间英夫利西单抗谷浓度与溃疡性结肠炎患者的内镜愈合及组织学愈合相关。

研究设计与样本

  • 多中心回顾性队列研究,纳入2008年2月至2016年3月接受英夫利西单抗维持治疗且在三周内完成内镜评估与治疗药物监测的连续中重度溃疡性结肠炎患者,共评估56例患者的70次结肠镜检查,按事件进行分析。

主要发现

  • 内镜愈合组英夫利西单抗谷浓度中位数11.3 μg/mL(四分位距7.6-14.5),未愈合组6.3 μg/mL(0-9.8),P < .001。
  • 组织学愈合组谷浓度中位数11.1 μg/mL(6.7-14.5),未愈合组6.7 μg/mL(0-9.9),P = .002。
  • 受试者工作特征分析确定与内镜愈合相关的谷浓度阈值为7.5 μg/mL(曲线下面积0.758),与组织学愈合相关的阈值为10.5 μg/mL(曲线下面积0.721)。
  • 多因素logistic回归显示谷浓度≥7.5 μg/mL(P = .013;OR 4.3;95%CI 1.4-13.3)与内镜愈合独立相关,≥10.5 μg/mL(P = .013;OR 3.8;95%CI 1.3-11)与组织学愈合独立相关。

关键数值与推荐

  • 内镜愈合定义为Mayo内镜亚评分≤1。
  • 组织学愈合定义为无活动性炎症或仅有局灶性轻度活动性炎症。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoscopic and histologic healing are emerging as new therapeutic goals in ulcerative colitis (UC), as these endpoints are associated with less relapse, hospitalization and colectomy. AIM: To investigate the association of serum infliximab trough concentrations during maintenance therapy with endoscopic or histologic healing in UC. METHODS: In this multi-center retrospective cohort study, we included consecutive patients with moderate-to-severe UC on infliximab maintenance therapy who had an endoscopic evaluation and underwent therapeutic drug monitoring within three months of the colonoscopy, between February 2008 and March 2016. Per event analysis was performed. Endoscopic healing was defined as Mayo endoscopic sub-score of ≤1. Histologic healing was defined as no or only focal mild active inflammation. RESULTS: Seventy colonoscopies from 56 patients were evaluated. Infliximab trough concentrations (median [interquartile range]) were significantly higher in patients with endoscopic (11.3 [7.6-14.5] vs 6.3 [0-9.8] μg/mL, P < .001) or histologic (11.1 [6.7-14.5] vs 6.7 [0-9.9] μg/mL, P = .002) healing, respectively, compared to patients without healing. Receiver-operating characteristic analyses identified infliximab trough concentration thresholds of 7.5 (area under the curve [AUC]: 0.758) and 10.5 (AUC: 0.721) μg/mL to be associated with endoscopic and histologic healing, respectively. Multiple logistic regression analysis identified infliximab trough concentration ≥7.5 (P = .013; odds ratio [OR]: 4.3; 95% confidence intervals [CI]: 1.4-13.3) and ≥10.5 μg/mL (P = .013; OR: 3.8; 95% CI: 1.3-11) as independent factors associated with endoscopic and histologic healing, respectively. CONCLUSIONS: This study demonstrated that infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in patients with UC.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Papamichael K, Rakowsky S, Rivera C, et al. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. Aliment Pharmacol Ther. 2017. PMID: 29210094. doi:10.1111/apt.14458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。